NEXLIZET
Peakbempedoic acid and ezetimibe
NDAORALTABLET
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
NEXLIZET (bempedoic acid and ezetimibe) is adenosine triphosphate-citrate lyase inhibitors [moa]. First approved in 2020.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXLIZET is a fixed-dose combination tablet containing bempedoic acid and ezetimibe, approved by the FDA on February 26, 2020. It works through dual mechanisms: bempedoic acid inhibits adenosine triphosphate-citrate lyase to reduce cholesterol synthesis, while ezetimibe inhibits cholesterol absorption in the intestine. The combination is indicated for patients with elevated LDL cholesterol who require additional lipid-lowering therapy beyond statins or as an alternative for statin-intolerant patients.
$0.0BPart D
14.1 years to LOEMechanism of Action
Adenosine Triphosphate-Citrate Lyase Inhibitors
Pharmacologic Class:
Adenosine Triphosphate-Citrate Lyase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEXLIZET currently has zero linked open positions in the available dataset, suggesting stable staffing levels or limited active recruitment. Roles supporting this product typically include brand managers focused on cardiovascular/lipid management, medical science liaisons engaging cardiologists and primary care physicians, and field sales representatives. Key competencies include knowledge of lipid metabolism pathways, familiarity with statin-intolerant patient management, and understanding of Medicare/Part D formulary dynamics.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.